Bio-Active Company LIMITED

Bio-Active Company LIMITED is a for-profit limited liability company headquartered in Thailand (UEI: QDNHLTY9E5E8) that specializes in providing genetic sequencing systems, laboratory reagents, equipment maintenance services, and testing materials to support infectious disease monitoring and research programs conducted by U.S. government agencies in Southeast Asia. Registered in SAM.gov since March 28, 2013, with registration expiring August 20, 2026, the company leverages its strategic location and supply chain capabilities in Thailand to deliver biomedical goods and specialized laboratory support services to various civilian and defense agencies operating in the region. Bio-Active Company LIMITED has established itself as a critical vendor for U.S. government health initiatives focused on disease surveillance and research activities across Thailand and Cambodia.

Bio-Active Company LIMITED has delivered an extensive portfolio of goods and services through prime federal contract awards spanning from 2021 through 2025, with a combined contract value exceeding $1.8 million. The company has provided Illumina genetic sequencing platforms, including MiSeq, NextSeq, and NextSeq 2000 systems, along with associated reagents, consumables, and components to support DNA and RNA sequencing of clinical, environmental, and vector-borne disease samples. Maintenance and operational support services for sequencing instruments represent a significant portion of the company's federal work, with annual maintenance agreements for Illumina NextSeq 2000 systems valued between $47,610 and $168,730. Bio-Active Company LIMITED has also procured and delivered specific reagent kits and testing materials for infectious disease detection, including reagents for influenza, dengue, chikungunya, SARS-CoV-2, and COVID-19 detection kits on behalf of the Centers for Disease Control and Prevention. Primary funding agencies include the Department of the Army, Defense Health Agency, Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, Chief of Naval Operations, and the Bureau of European and Eurasian Affairs. Most contract awards have been issued as firm fixed-price purchase orders and Blanket Purchase Agreement calls, with no small business set-aside provisions applied to any awards. The company has served the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand, and NIAID facilities in Cambodia as primary end-users of its goods and services.

Bio-Active Company LIMITED holds a single-award Blanket Purchase Agreement with the U.S. Department of Defense's Medical Command (MEDCOM), awarded May 1, 2021, with an ultimate completion date of April 30, 2026. This BPA provides for the delivery of maintenance, emergency, and operational services for Illumina MiSeq genetic sequencing systems and related instruments used to support infectious disease monitoring and research programs. The BPA has generated multiple firm fixed-price task orders valued between approximately $26,000 and $29,000 per call, with performance periods ranging from one to three years. The MEDCOM BPA serves as the umbrella vehicle through which numerous civilian and defense agencies—including the Centers for Disease Control and Prevention, Department of Defense components, and National Institutes of Health—issue task orders for sequencing instrument maintenance and support at facilities in Thailand. The agreement is structured with no small business set-aside designation and represents the foundational contracting mechanism that has enabled Bio-Active Company LIMITED to maintain ongoing support relationships with multiple U.S. government agencies conducting infectious disease surveillance and research activities in Southeast Asia.